Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05554731
Other study ID # 2020C03067
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date October 30, 2023

Study information

Verified date September 2022
Source First Affiliated Hospital of Wenzhou Medical University
Contact Chen ChengShui, doctor
Phone 86-13806889081
Email wzchencs@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Massive hemoptysis is a serious disease of respiratory system, which seriously endangers the life of patients. There are obvious difficulties in the treatment of hemoptysis. In the traditional treatment, patients still have the risk of massive hemoptysis and suffocation, and the risk control in the treatment process cannot be ensured. Intra - airway interventional therapy, especially the hemostatic technique of intra - airway balloon catheter, is an important means to control the risk of hemoptysis. However, the current intraairway balloon catheter therapy technology is immature, complicated and difficult to operate, and the cost is high. There is a lack of special balloon for hemostasis, and the balloon borrowed for other purposes cannot meet the needs of hemoptysis treatment. Therefore, it is urgent to develop a new balloon catheter for airway hemostasis, which has simple technical operation, easy to master and popularize, efficient and safe function and structure. According to this requirement, this project designed and developed hemostatic balloon catheter with multiple functions such as self-guiding, anti-displacement, anti-leakage and detachable rear end, so as to make the treatment of massive hemoptysis more safe and effective, simpler and faster, so as to be widely applied in clinical practice.


Description:

This study are aimed to investigate the safety and effectiveness of the new intraairway hemostatic balloon catheter in the treatment of massive hemoptysis, as well as the superior efficacy compared with the traditional treatment strategy of massive hemoptysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 30, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The patients were 18-75 years, male or non-pregnant female; - Meet the clinical definition of massive hemoptysis (blood loss =100ml each time or =500ml 24h); - The patient/legal authorized representative understood the purpose and procedure of the test and voluntarily signed the informed consent. Exclusion Criteria: - Patients and their family members have no subjective treatment intention;Patients fail to cooperate or sign preoperative informed consent; - The obvious effect of balloon catheter therapy is not ideal; - Severe arrhythmia, acute myocardial ischemia; - blood pressure is not effectively controlled (diastolic blood pressure =95mmHg or systolic blood pressure =150mmHg); - Severe coagulopathy; - Severe organ insufficiency (except respiratory insufficiency); - Allergic to narcotic drugs; - Pregnant women, those who are breast-feeding or trying to conceive; - Patients who do not wish to sign informed consent; - Patients who failed to follow up; - Other patients deemed unsuitable for the study by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
a New Balloon Catheter for Intraairway Hemostasis
In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
Traditional Therapy
A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.

Locations

Country Name City State
China The first affiliated hospital of wenzhou medical university Wenzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Wenzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immediate intraoperative success rate Immediate intraoperative success rate Immediately after surgery
Primary Success rate of hemostasis 1 day after operation Success rate of hemostasis 1 day after operation 1 day after operation
Primary Intraoperative complication Significant increase in hemoptysis requiring other emergency management or suspension of operations, asphyxia, death, new arrhythmias, persistent worsening hypoxemia. During surgery
Secondary Success rate of hemostasis 3 days and 1 and 2 weeks after operation Success rate of hemostasis 3 days and 1 and 2 weeks after operation 3 days and 1 and 2 weeks after operation
Secondary The bleeding time The bleeding time From date of randomization until the date of second operation , assessed up to 13 months
Secondary The operation rate of balloon occlusion again The operation rate of balloon occlusion again From date of randomization until the date of second operation , assessed up to 13 months
Secondary Measurement indexes of follow-up treatment measures Including CTA and its preparation time, rate of arterial embolization surgery and proportion of emergency surgery. From date of randomization until the date of second operation , assessed up to 13 months
Secondary Anesthesia complications Complications after anesthesia including hypotension and shock, postoperative new tracheal intubation, coma and cerebrovascular accident. During surgery
Secondary hyoxemia For more than 2 hours, oxygen saturation drops below 90%. From date of randomization until the date of second operation , assessed up to 13 months
Secondary Other complications venous thrombosis of lower limbs From date of randomization until the date of second operation , assessed up to 13 months
Secondary Balloon closure operation time Compared with the traditional dilated balloon group, the operation time of balloon closure was calculated up to 13 months
Secondary success rate of placement success rate of placement From date of randomization until death , assessed up to 13 months
Secondary time and incidence of balloon leakage time and incidence of balloon leakage (under the premise of two inflations per day) From date of randomization until the date of second operation , assessed up to 13 months
Secondary incidence of balloon displacement incidence of balloon displacement (including the discount and distortion in the airway) From date of randomization until the date of second operation , assessed up to 13 months
Secondary Nasal and bronchial mucosa injury Compared with the traditional dilated balloon group, the damage of nasal and bronchial mucosa after balloon closure was observed up to 13 months
Secondary Rate of hemoptysis after balloon occlusion compared with traditional balloon dilation group up to 13 months
Secondary Rate of re-balloon closure compared with traditional balloon dilation group up to 13 months
Secondary Incomplete completion rate of balloon closure operation compared with traditional balloon dilation group up to 13 months
See also
  Status Clinical Trial Phase
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Completed NCT00387374 - Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Phase 2
Completed NCT05513248 - Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019
Recruiting NCT05634200 - Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan
Recruiting NCT06144398 - Single Use Flexible Bronchoscopes in Interventional Pulmonary Procedures N/A
Completed NCT01278199 - Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance N/A
Recruiting NCT04961528 - ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. Phase 3
Recruiting NCT05786781 - An Exploratory Study on the Application of Transarterial CT Angiography in the Interventional Treatment of Hemoptysis N/A
Completed NCT04087135 - Comparison of Intubation With Direct Laryngoscopy or Videolaryngoscopy in an Hemoptysis Simulated Situation on Human Cadaver Embalmed With Thiel's Method N/A
Recruiting NCT03270735 - A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection Phase 4
Completed NCT00929565 - Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy N/A
Completed NCT01171768 - The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis N/A
Withdrawn NCT01167764 - Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis Phase 3
Completed NCT03126968 - Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies Phase 2/Phase 3
Completed NCT02781597 - Efficacy of Tranexamic Acid in Hemoptysis Phase 3
Recruiting NCT05648656 - TXA Nebulization for the Treatment of Hemoptysis Phase 3
Completed NCT04771923 - Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding N/A
Recruiting NCT06145191 - Prophylactic Tranexamic Acid Versus Adrenaline During Flexible Bronchoscopy N/A
Completed NCT04770675 - Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.
Completed NCT06067997 - Prevalence Of Pulmonary Embolism In Patients With HEmoptysis (POPEIHE)